Diabetic macular oedema
In the RESTORE extension study, Prof Paolo Lanzetta from the Department of Ophthalmology, University of Udine introduced results from 240 patients with diabetic macular oedema (DME) who received individualised treatment with ranibizumab in a regimen consistent with the European Union label, the standard of care in wet AMD. The data presented at the 12th EURETINA Congress in Milan, Italy, showed that patients who were originally treated with ranibizumab received an average of 13.9 injections over three years. The mean of seven letters of visual acuity gained in the RESTORE core study were maintained with an average of 3.7 injections in the second year and 2.7 in the third year.Â
Latest Articles
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Nutrition and the Eye: A Recipe for Success
A look at the evidence for tasty ways of lowering risks and improving ocular health.
New Award to Encourage Research into Sustainable Practices
Sharing a Vision for the Future
ESCRS leaders update Trieste conference on ESCRS initiatives.
Extending Depth of Satisfaction
The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.
Conventional Versus Laser-Assisted Cataract Surgery
Evidence favours conventional technique in most cases.
AI Scribing and Telephone Management
Automating note-taking and call centres could boost practice efficiency.